FogPharma

This week, the Alldus podcast hosted Fog Chief Data Officer, Brandon Allgood, Ph.D., for a discussion on his career applying machine learning and large-scale computational methods to improve human health. The conversation highlighted Brandon’s industry leadership and expertise in this important discipline and how we’re combining biology and chemistry with data science advances to revolutionize the discovery and development of transformational medicines.    Our data science efforts are robust and growing at Fog, and we’re building the team to support that growth. We’re currently hiring for the following roles on Brandon’s team:     - Sr. Scientist, Machine Learning   - Principal Data Product Engineer  - Sr. Data Scientist, Cheminformatics    Learn more about these positions here: https://bit.ly/3VSwmAx     #TeamFogPharma #BiotechJobs #machinelearning #artificialintelligence #AI  

Join us in welcoming Christopher Martin, Ph.D., our new Vice President of Manufacturing and latest executive to join #TeamFogPharma. Chris’ expertise in peptide drug manufacturing and his experience producing over one hundred drugs and therapeutic candidates across all lifecycle stages will be invaluable as he leads the management and strategy of our supply of clinical and future commercial products worldwide. We’re thrilled to have you on the team, Chris! #oncology #biotech #manufacturing

This piece by Ned Pagliarulo in BioPharma Dive is a great primer on our recently announced collaboration with ARTBIO and the excitement surrounding #radiopharmaceuticals overall. As Ned writes, “The radiopharma field is booming, drawing substantial investment from large companies and venture capital firms eager to capitalize on the drugs’ potential to balance cancer-killing potency with better safety.” The Helicon-enabled radioligand therapies we will co-develop will benefit from the hyper-tunability of Helicons, to control the drugs’ distribution and half-life, and from the uniqueness of lead-212, one of the most promising isotopes for radiopharmaceutical use. Check out this photo of our teams together kicking off our partnership, and read the story here: https://bit.ly/3KN2zm5 #radioligandtherapy #cancer #oncology #peptides #Helicons #patients  

We were very grateful to have Regina Barzilay — one of the world’s leading AI/machine learning researchers and a Distinguished Professor for AI and Health at CSAIL MIT — join us recently to discuss the fast-evolving landscape of machine learning in drug discovery. Dr. Barzilay presented some of her own pioneering work in building AI models to optimize small-molecule drug design and protein engineering. She also joined a deeper discussion with our scientific team to explore the specific challenges and opportunities in molecular machine learning, one of the core computational approaches being advanced by our in-house data science team that informs our drug discovery work. Thank you, Dr. Barzilay, for sharing your insights and being a thought partner as we continue to push the bounds of what’s possible. #machinelearning #artificialintelligence #AI #biotechnology

We were very proud to have #TeamFogPharma along with our families and friends walking in the Boston Pride Parade on Saturday! The event was a joyful experience in celebrating #PrideMonth, honoring the rich history and many local activists past and present who champion the rights of LGBTQ+ people worldwide, and demonstrating Fog’s commitment to advancing equity and inclusivity for the LGBTQ+ community.

Don’t miss FogPharma at the upcoming Goldman Sachs 45th Annual Global Healthcare Conference. CEO Mathai Mammen, M.D., Ph.D. will give a company presentation on Monday, June 10, sharing the latest on Fog’s ongoing clinical trial of FOG-001, our preclinical pipeline of novel cancer therapeutics, and the exceptional potential of our Helicon peptide technology. Hope to see you there! 

FogPharma CEO Mathai Mammen, M.D., Ph.D. was honored by Timmerman Report among an inspiring group of fellow Asian American & Pacific Islander biopharma leaders to celebrate #AAPIHeritageMonth.    A diverse biopharma industry is essential if we are to create extraordinary medicines. Enriching our industry’s leadership with perspectives from AAPI and other historically underrepresented groups will enrich our cross-cultural fluency and ultimately our ability to achieve our mission to make a transformative impact for people and patients from all backgrounds.   https://bit.ly/3Kn3N70     #AAPIrepresentation #diversity #inclusion

Last week, Fog gathered for our first two-day company retreat in Meredith, NH, on Lake Winnipesaukee. The theme of the offsite was “Connect, Inspire, Innovate” where we kicked off the time with a conversation with a patient-care partner couple, Tracy and Jason Binder. Their story and experiences of living with cancer reminded us of our purpose and the urgent need for new, more effective treatments. We also spent time learning from each other about the innovative projects and solutions happening across the organization and coming up with ways to further our mission over the next several years.    Most importantly, the offsite allowed us to deepen the connections between us that power our work each day and enable us to create extraordinarily impactful medicines.      Check out some of the highlights from our time together! 👇☀️🌳 #TeamFogPharma #teamdevelopment 

Please join us as Kyri Papadopoulos, M.D., from The START Center for Cancer Care presents our Trials in Progress poster at #ASCO2024 this weekend in Chicago, IL! Dr. Papadopoulos will be presenting the design of our first-in-human (FIH) Phase 1/2 trial of FOG-001, a first-in-class inhibitor of β-catenin that directly blocks β-catenin’s interaction with the T-cell factor (TCF) family of transcription factors, the most downstream node in the Wnt pathway.   The ASCO annual conference gathers leaders from around the world to share the latest advancements in oncology and provides an opportunity to forge connections with others who are as passionate about transforming what is possible for cancer patients as we are. Our abstract and presentation location can be found at: https://bit.ly/4bTAQMt   #drugdiscovery #oncology #cancerresearch

Congratulations to the talented chemists on #TeamFogPharma who will be heading to grad school: Lia Baker to Columbia, Jesper Andersson to UCLA, and Gregory Valtierra to MIT! They've each been vital contributors to building our team and driving forward our Helicon research, and we’re sure they’ll make the same big impact in their graduate studies and beyond.   At Fog, we’re big believers in growth mindset and lifelong learning. We’re so proud that these scientists will be continuing their education and taking their learnings from Fog forward into their future careers. #drugdiscovery #oncology #biotechnology